瑞舒伐他汀联合依折麦布在心肌梗死患者中的应用效果及对炎症因子水平的影响

Effect of Rosuvastatin combined with Ezetimibe in patients with myocardial infarction and its influence on the level of inflammatory factors

目的探讨瑞舒伐他汀联合依折麦布在心肌梗死患者中的应用效果及对炎症因子水平的影响。方法选取2019年1月—2020年1月大连市第三人民医院收治的94例心肌梗死患者作为研究对象,按照随机数字表法分为研究组(47例)与对照组(47例)。对照组应用瑞舒伐他汀治疗,研究组应用瑞舒伐他汀联合依折麦布治疗。比较两组患者的炎症因子水平[肿瘤坏死因子(TNF-α)、超敏C反应蛋白(hs-CRP)、白介素6(IL-6)]、治疗效果、血脂水平[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)]、不良反应总发生率以及心肌酶水平[乳酸脱氢酶(LDH)、肌酸激酶(CK)、磷酸肌酸同工酶(CK-MB)]。结果研究组的TNF-α、hs-CRP、IL-6水平低于对照组,差异有统计学意义(P<0.05)。研究组的总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组的TC、TG、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后,研究组的TC、TG、LDL-C水平低于对照组,差异有统计学意义(P<0.05)。研究组的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。治疗前,两组的LDH、CK、CK-MB比较,差异无统计学意义(P>0.05);治疗后,研究组的LDH、CK、CK-MB水平低于对照组,差异有统计学意义(P<0.05)。结论心肌梗死患者应用瑞舒伐他汀联合依折麦布进行治疗,具有一定的治疗效果,可以有效改善心肌梗死患者的临床症状,同时,还可以有效降低心肌梗死患者的血脂水平,抑制炎症反应,降低出现不良反应的情况,安全性高,在临床上值得进一步应用推广。

Objective To explore the effect of Rosuvastatin combined with Ezetimibe in patients with myocardial infarction and its influence on the level of inflammatory factors.Methods A total of 94 patients with myocardial infarction admitted to the Third People′s Hospital of Dalian from January 2019 to January 2020 were selected as the research subjects and divided into the study group(47 cases)and the control group(47 cases)according to the random number table method.The control group was treated with Rosuvastatin,and the study group was treated with Rosuvastatin combined with Ezetimibe.The inflammatory factor levels(tumor necrosis factor-α[TNF-α],hypersensitive C-reactive protein[hs-CRP]and interleukin 6[IL-6]),treatment effect and blood lipid levels(total cholesterol[TC],triylglycerol[TG],low density lipoprotein cholesterol[LDL-C]),the total incidence of adverse reactions and myocardial enzyme levels(lactate dehydrogenase[LDH],creatine kinase[CK],creatinine kinase isoenzyme[CK-MB])of two groups were compared.Results The levels of TNF-α,hs-CRP and IL-6 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of TC,TG,LDL-C between the two groups(P>0.05).After the treatment,the levels of TC,TG,LDL-C in the study group were lower than those in the control group,with statistically significant difference(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of LDH,CK and CK-MB between the two groups(P>0.05).After the treatment,the levels of LDH,CK and CK-MB in the study group were lower than those in the control group,with statistically significant difference(P<0.05).Conclusion Patients with myocardial infarction were treated with Rosuvastatin combined with Ezetimibe,with a certain therapeutic effect,could effectively improve the clinical symptoms in patients with myocardial infarction,at the same time,also can effectively reduce the blood lipid levels in patients with myocardial infarction,inhibiting inflammatory reaction,reduce the adverse reaction condition,high safety,it′s worth popularizing further application in clinic.